Stockreport

Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise [Seeking Alpha]

Tango Therapeutics, Inc.  (TNGX) 
PDF Vopimetostat, the lead PRMT5 inhibitor, advances to a pivotal trial in 2L MTAP-deleted pancreatic cancer, with FDA-aligned design and robust enrollment. TNGX boasts a [Read more]